340 related articles for article (PubMed ID: 26288839)
1. The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.
Stark MS; Klein K; Weide B; Haydu LE; Pflugfelder A; Tang YH; Palmer JM; Whiteman DC; Scolyer RA; Mann GJ; Thompson JF; Long GV; Barbour AP; Soyer HP; Garbe C; Herington A; Pollock PM; Hayward NK
EBioMedicine; 2015 Jul; 2(7):671-80. PubMed ID: 26288839
[TBL] [Abstract][Full Text] [Related]
2. A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.
Ono S; Oyama T; Lam S; Chong K; Foshag LJ; Hoon DS
Oncotarget; 2015 Mar; 6(9):7053-64. PubMed ID: 25749524
[TBL] [Abstract][Full Text] [Related]
3. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
4. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase.
Deichmann M; Kahle B; Moser K; Wacker J; Wüst K
Br J Cancer; 2004 Aug; 91(4):699-702. PubMed ID: 15280926
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.
Bedikian AY; Wei C; Detry M; Kim KB; Papadopoulos NE; Hwu WJ; Homsi J; Davies M; McIntyre S; Hwu P
Am J Clin Oncol; 2011 Dec; 34(6):603-10. PubMed ID: 21150567
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
8. A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
[TBL] [Abstract][Full Text] [Related]
9. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
10. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis.
Weide B; Elsässer M; Büttner P; Pflugfelder A; Leiter U; Eigentler TK; Bauer J; Witte M; Meier F; Garbe C
Br J Cancer; 2012 Jul; 107(3):422-8. PubMed ID: 22782342
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma.
Henry L; Lavabre-Bertrand T; Douche T; Uttenweiler-Joseph S; Fabbro-Peray P; Monsarrat B; Martinez J; Meunier L; Stoebner PE
Exp Dermatol; 2010 Dec; 19(12):1054-9. PubMed ID: 20707810
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.
Ahmed FE; Ahmed NC; Vos PW; Bonnerup C; Atkins JN; Casey M; Nuovo GJ; Naziri W; Wiley JE; Mota H; Allison RR
Cancer Genomics Proteomics; 2013; 10(3):93-113. PubMed ID: 23741026
[TBL] [Abstract][Full Text] [Related]
13. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
14. Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III-IV malignant melanoma.
Bánfalvi T; Boldizsár M; Gergye M; Gilde K; Kremmer T; Ottó S
Pathol Oncol Res; 2002; 8(3):183-7. PubMed ID: 12515998
[TBL] [Abstract][Full Text] [Related]
15. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
16. Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine.
Mumford SL; Towler BP; Pashler AL; Gilleard O; Martin Y; Newbury SF
Biomolecules; 2018 Apr; 8(2):. PubMed ID: 29701682
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
[TBL] [Abstract][Full Text] [Related]
18. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma.
Xu H; Yang Y; Zhao H; Yang X; Luo Y; Ren Y; Liu W; Li N
Tumour Biol; 2016 Jan; 37(1):447-53. PubMed ID: 26224475
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.
Heinzelmann J; Unrein A; Wickmann U; Baumgart S; Stapf M; Szendroi A; Grimm MO; Gajda MR; Wunderlich H; Junker K
Ann Surg Oncol; 2014 Mar; 21(3):1046-54. PubMed ID: 24242678
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
Egberts F; Pollex A; Egberts JH; Kaehler KC; Weichenthal M; Hauschild A
Onkologie; 2008 Jul; 31(7):380-4. PubMed ID: 18596385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
